American Society of Hematology

Figure 3.

MRD kinetics in individual patients (MRD efficacy-evaluable population). uMRD was defined as <1 CLL cell per 104 mononuclear cells in samples with a minimum of 200 000 leukocytes (<10−4). Low-level MRD was defined as between 1 CLL cell per 104 and 1 cell per 102 mononuclear cells (≥10−4 to <10−2). One patient was excluded from the MRD analysis because of an undetectable MRD result at screening assumed to be due to the use of anti-CD20 <2 months before starting the trial. High-level MRD was defined as ≥1 CLL cell per 102 mononuclear cells (≥10−2). del, deletion; mut, mutated; ven, venetoclax.

MRD kinetics in individual patients (MRD efficacy-evaluable population). uMRD was defined as <1 CLL cell per 10⁴ mononuclear cells in samples with a minimum of 200 000 leukocytes (<10⁻⁴). Low-level MRD was defined as between 1 CLL cell per 10⁴ and 1 cell per 10² mononuclear cells (≥10⁻⁴ to <10⁻²). One patient was excluded from the MRD analysis because of an undetectable MRD result at screening assumed to be due to the use of anti-CD20 <2 months before starting the trial. High-level MRD was defined as ≥1 CLL cell per 10² mononuclear cells (≥10⁻²). del, deletion; mut, mutated; ven, venetoclax.

This Feature Is Available To Subscribers Only